Science and Discovery

Revolution Medicines

1 article

Microscopic view of cancer cells being targeted by a glowing therapeutic agent, representing Revolution Medicines' experimental drug.
Cosmos & Space

Revolution Medicines' Experimental Pancreatic Cancer Drug Shows Promise

Revolution Medicines' experimental drug daraxonrasib doubled the median overall survival for patients with metastatic pancreatic cancer to 13.2 months in its pivotal Phase 3 trial.

David Grossman·May 31, 2026